Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience

Table 2

Patients’ antiresorptive therapy.

Drug prescribed	Oncologic patients		Osteoporotic patients		Total
	(172)		(72)		(244)
		%		%		%
Zoledronate	149	86.6%	5	6.9%	154	63.1%
Denosumab	11	6.5%	2	2.9%	13	5.4%
Denosumab + zoledronate	3	1.7%	—	—	3	1.2%
Alendronate	—	—	34	47.2%	34	13.9%
Clodronate	4	2.3%	10	13.9%	14	5.7%
Risedronate	3	1.7%	7	9.7%	10	4.1%
Ibandronate	1	0.6%	7	9.7%	8	3.3%
Pamidronate	1	0.6%	—	—	1	0.4%
Off-label therapy	—	—	7	9.7%	7	2.9%